Windlas Biotech’s share of Rs 401.53 crore is subscribed 22.46 times. The company will allot the shares from Wednesday i.e. 11 August 2021. Its shares are trading at a premium of Rs 80 i.e. Rs 540 in the gray market. This is 17.4 per cent higher than its IPO price. Windlas Biotech does not have any peer company listed. It competes only with unlisted companies like Theon Pharma, Synokem Pharma, and Innova Captab.
Shares of Windlas Biotech will be listed on August 17, 2021. The amount blocked in the ASBA account will be unblocked on 12th August. If you get its shares, then it will be credited to your depository on August 13. Investors who have applied for its shares can check the status from the websites of BSE or its registrar. They are responsible for IPO allotment and refund processing. SEBI-registered investment advisor INDmoney has said in its report that the company is the leader in the market. It has good growth in revenue and strong growth prospects. In such a situation, this issue is very good for the long term.
Chemplast Sanmar’s IPO opens, invest money or not – know what is the opinion of experts
How to check share allotment status from Registrar Link
Go to Intime India website. There type – ‘Windlas Biotech — IPO’. Enter any one of these options in the check box of PAN Number, Application or Depository / Client ID. Enter the captcha code and hit the submit button. After this, the number of shares allotted by you will appear on the screen along with the number of shares applied for.
How to check share allotment status on BSE website
Click on this link – (https://www.bseindia.com/investors/appli_check.aspx). In the drop down list type ‘Windlas Biotech Ltd’. After that put the pan. Then click on ‘I am not a Robot’. Then click on the Search tab. You will see the status of the shares received.
35 percent reserve for retail investors
More than 50 percent of the shares to be issued under the IPO will be reserved for QIBs. 35 percent of the shares have been kept for retail investors and the remaining 15 percent for non-institutional investors (NIIs). The rest is reserved for retail investors. The special thing about this IPO is that no pharma formulation company is listed yet. If Windlas is listed, it will be the first such company. The company will use the funds raised from the IPO to buy equipment to increase capacity.
What does the company do?
The company is one of the top five companies in the Pharmaceuticals Formulation Contract Development and Manufacturing Organization (CDMO) industry in the country. It has been involved in the development and sales of complex generic products from product discovery to its development, licensing and generic products (drugs and nutracells). It also sells its over the counter and its own branded products. The company will use the capital raised from the IPO to purchase equipment needed to increase the production capacity of the Dehradun-based factory.